Xtant Medical Holdings, a leader in the development and commercialization of regenerative medicine products for orthopedic and neurosurgical applications, has entered into a strategic partnership with B2i Digital. This collaboration is designed to provide investors with a deeper understanding of Xtant's orthobiologics platform and its significant market opportunity. The initiative underscores the company's commitment to transparency and investor education, highlighting its vertically integrated model and robust product pipeline.
The partnership comes at a time when Xtant Medical is experiencing notable growth, with fiscal year 2024 revenue reaching $117.5 million, marking a 29% increase from the previous year. This financial performance is supported by a comprehensive portfolio that includes bone-healing grafts, growth-factor biologics, and other innovative products. The company's access to a $2.5 billion U.S. orthobiologics market, part of a $10.1 billion global spine market, positions it as a key player in the medical technology industry.
David Shapiro, CEO of B2i Digital, emphasized the significance of Xtant Medical's inclusion in their Featured Company program. 'Xtant's integrated platform and clear growth trajectory present a unique opportunity for investors interested in the medtech sector,' Shapiro noted. Sean Browne, CEO of Xtant Medical, added that the partnership with B2i Digital will enhance the company's ability to communicate its value proposition and growth story to the investment community.
This collaboration is not just about showcasing Xtant Medical's achievements but also about fostering a deeper connection with current and potential investors. By leveraging B2i Digital's extensive network and digital marketing expertise, Xtant aims to amplify its visibility and appeal in the competitive medical technology landscape. The move reflects a broader trend of healthcare companies seeking innovative ways to engage with investors and articulate their long-term value propositions.
